Phenotypic diversity and prognosis of adult T-cell leukemia

Kamihira, Shimeru; Sohda, Hisashi; Atogami, Sunao; Toriya, K; Yamada, Yasuaki; Tsukazaki, Kunihiro; Momita, Saburo; Ikeda, Shu‐ichi; Kusano, Mao; Amagasaki, T; Kinoshita, K; Tomonaga, Masao

doi:10.1016/0145-2126(92)90168-7

Cited by 101 publications

(64 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This must be confirmed by clonal integration of HTLV-I provirus in the host genome. The predominant immunological phenotype of neoplastic cells is helper T-cell, CD3 + , CD4 + , L-selectin + , CD25 + , CD45RA + , HLA-DR + , CD29 À , and CD45RO À in peripheral blood, or CD3 + , CD4 + , L-selectin + , CD29 + , CD45RO + , HLA-DR + , and CD45RA À in the skin and lymph nodes [14,15]. Phenotypic as well as morphological heterogeneity of ATL cells and heterogeneity of CD45R isoform expression on ATL cells can be found in different organs.…”

Section: Diagnosis Criteriamentioning

confidence: 99%

Current views in HTLV-I-associated adult T-cell leukemia/lymphoma

Nicot

2005

Am. J. Hematol.

104

View full text Add to dashboard Cite

Epidemiological studies have demonstrated that the relative percentage of malignant lymphoid proliferations varies widely according to geographical location and ethnic populations. HTLV-I is the etiological agent of adult T-cell leukemia/lymphoma (ATLL) and is also associated with cutaneous T-cell lymphoma (CTCL). However, a definite role of HTLV-I in mycosis fungoides (MF) and/or Sezary syndrome (SS) remains controversial. While most HTLV-I-infected individuals remain asymptomatic carriers, 1-5% will develop ATLL, an invariably fatal expansion of virus-infected CD4 + T cells. This low incidence and the long latency period preceding occurrence of the disease suggest that additional factors are involved in development of ATLL. In this review, diagnosis, clinical features, and molecular pathogenesis of HTLV-I are discussed. Am.

show abstract

Section: Diagnosis Criteriamentioning

confidence: 99%

Current views in HTLV-I-associated adult T-cell leukemia/lymphoma

Nicot

2005

Am. J. Hematol.

104

View full text Add to dashboard Cite

show abstract

“…CD16expres-sion, which is the most constant marker of NKcells (18), was negative, and the histological features of the ATLcells in peripheral blood were no different from those of typical CD4+/ 8-/56-ATL( 1 9). Although ATLcells were previously reported to occasionally express NCAM (20)(21)(22)(23), there has been only one case report of a detailed clinical course in which the patient showed unusual involvement of the gastrointestinal tract during the course of the disease (22). It has been reported that at least roughly 10% of all ATL patients manifest CNS involvement (24).…”

Section: Resultsmentioning

confidence: 99%

Adult T-cell Leukemia (ATL) Cells which Express Neural Cell Adhesion Molecule (NCAM) and Infiltrate into the Central Nervous System.

et al. 2002

View full text Add to dashboard Cite

Weencountered a patient with adult T-cell leukemia/lymphoma (ATL) which expressed neural cell adhesion molecule (NCAM). The tumor cells markedly infiltrated the central nervous system (CNS) during the course of the ATL. The patient died 20 months after disease onset, which was considered to be early in the course. During the invasion of the CNS, the surface phenotype of the peripheral blood ATL cells by flow cytometric analysis was CD2+, CD3+, CD4+, CD7-, CD8-, CD16-, NCAM(CD56)+, HLA-DR-. We speculate that the infiltration ofATLcells into the CNSwas closely related to the expression of the NCAM in this patient. (Internal Medicine 41 : 34-38, 2002)

show abstract

“…2 In the present case, T cell markers (CD2, CD3, CD4, CD5, and CD8) were not expressed. The incidence of double-negative (CD4 − /CD8 − ) ATL was 7%, 3 while it has been reported that lack of CD2, CD3, and CD5 antigens worsens prognosis. Furthermore, the lymphoma cells of the presented case had a clonal EBV genome.…”

Section: Figurementioning

confidence: 99%

“…Its product, E2A-HLF chimeric protein, is responsible for the pathogenesis of t(17;19)-ALL in that it inhibits lymphoid precursor cells from undergoing apoptosis. 2,3 This paper reports the establishment of a new B-lineage cell line with t(17;19), YCUB-2, which expresses two different types of E2A-HLF fusion proteins.…”

Section: To the Editormentioning

confidence: 99%